Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
The cornerstone of the quality ecosystem is the implementation of the Quality Control Orders
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
40th DSIR Foundation Day celebration marks 16 more technology transfers from CSIR to MSMEs
The order, part of an international framework agreement is to be executed between February to April, 2025
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
DOVBLERON marks the 13th addition to Innovent’s commercial portfolio
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
The company's portfolio includes 21 commercialized products, 19 approved ANDAs, 4 CGT designations, 6 filed ANDAs, and 45 products in its pipeline
Subscribe To Our Newsletter & Stay Updated
